Piroxicam

DRUG INFORMATION

  ADULT
    - For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg
      given orally once per day.
      Source: US FDA label for piroxicam (PIROXICAM), section 'dosage and
      administration', retrieved 2026-08-29
    - Use the lowest effective dosage for shortest duration consistent with individual
      patient treatment goals ( 2 ) OA and RA: 20 mg once daily ( 2 )
      Source: US FDA label for piroxicam (PIROXICAM), section 'dosage and
      administration', retrieved 2026-08-29
    - Carefully consider the potential benefits and risks of piroxicam and other
      treatment options before deciding to use piroxicam. Use the lowest effective
      dosage for the shortest duration consistent with individual patient treatment
      goals [ see Warnings and Precautions (5) ] . After observing the response to
      initial therapy with piroxicam, the dose and frequency should be adjusted to suit
      an individual patient’s needs.
      Source: US FDA label for piroxicam (PIROXICAM), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Piroxicam has not been investigated in pediatric patients. The safety and
      effectiveness of piroxicam have not been established.
      Source: US FDA label for piroxicam (PIROXICAM), section 'pediatric use', retrieved
      2026-08-29

  RENAL IMPAIRMENT
    - Consider withdrawal of piroxicam in women who have difficulties conceiving ( 8.3 )
      8.1 Pregnancy Risk Summary Use of NSAIDs, including piroxicam, can cause premature
      closure of the fetal ductus arteriosus and fetal renal dysfunction leading to
      oligohydramnios and, in some cases, neonatal renal impairment.
      Source: US FDA label for piroxicam (PIROXICAM), section 'use in specific
      populations', retrieved 2026-08-29
    - Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks
      gestation or later in pregnancy has been associated with cases of fetal renal
      dysfunction leading to oligohydramnios, and in some cases, neonatal renal
      impairment.
      Source: US FDA label for piroxicam (PIROXICAM), section 'use in specific
      populations', retrieved 2026-08-29
    - Oligohydramnios/Neonatal Renal Impairment: If an NSAID is necessary at about 20
      weeks gestation or later in pregnancy, limit the use to the lowest effective dose
      and shortest duration possible.
      Source: US FDA label for piroxicam (PIROXICAM), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Discontinue if abnormal liver tests persist or worsen or if clinical signs and
      symptoms of liver disease develop ( 5.3 ) Hypertension: Patients taking some
      antihypertensive medications may have impaired response to these therapies when
      taking NSAIDs.
      Source: US FDA label for piroxicam (PIROXICAM), section 'warnings and cautions',
      retrieved 2026-08-29
    - Monitor blood pressure ( 5.4 , 7 ) Heart Failure and Edema: Avoid use of piroxicam
      in patients with severe heart failure unless benefits are expected to outweigh
      risk of worsening heart failure ( 5.5 ) Renal Toxicity: Monitor renal function in
      patients with renal or hepatic impairment, heart failure, dehydration, or
      hypovolemia.
      Source: US FDA label for piroxicam (PIROXICAM), section 'warnings and cautions',
      retrieved 2026-08-29
    - Additionally, patients with advanced liver disease and/or coagulopathy are at
      increased risk for GI bleeding.
      Source: US FDA label for piroxicam (PIROXICAM), section 'warnings and cautions',
      retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Use of NSAIDs, including piroxicam, can cause premature closure of
      the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios
      and, in some cases, neonatal renal impairment.
      Source: US FDA label for piroxicam (PIROXICAM), section 'pregnancy', retrieved
      2026-08-29
    - Because of these risks, limit dose and duration of piroxicam use between about 20
      and 30 weeks of gestation, and avoid piroxicam use at about 30 weeks of gestation
      and later in pregnancy (see Clinical Considerations, Data).
      Source: US FDA label for piroxicam (PIROXICAM), section 'pregnancy', retrieved
      2026-08-29
    - Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including piroxicam,
      at about 30 weeks gestation or later in pregnancy increases the risk of premature
      closure of the fetal ductus arteriosus.
      Source: US FDA label for piroxicam (PIROXICAM), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Infertility Females Based on the mechanism of action, the use of prostaglandin-
      mediated NSAIDs, including piroxicam, may delay or prevent rupture of ovarian
      follicles, which has been associated with reversible infertility in some women.
      Source: US FDA label for piroxicam (PIROXICAM), section 'nursing mothers',
      retrieved 2026-08-29
    - Published animal studies have shown that administration of prostaglandin synthesis
      inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture
      required for ovulation.
      Source: US FDA label for piroxicam (PIROXICAM), section 'nursing mothers',
      retrieved 2026-08-29
    - Small studies in women treated with NSAIDs have also shown a reversible delay in
      ovulation.
      Source: US FDA label for piroxicam (PIROXICAM), section 'nursing mothers',
      retrieved 2026-08-29